72 results about "Urinary Tract Diseases" patented technology

The present invention relates to a disorder of the lower urinary tract, and in particular, reducing the symptoms (including treatment) of interstitial cystitis in vivo. In a preferred embodiment, the present invention relates to treatment formulations and methods for reducing interstitial cystitis in patients.

The present invention relates to a compound represented by the formula

wherein ring A is a nitrogen-containing heterocycle optionally further having substituent(s), ring B is an aromatic ring optionally having substituent(s), ring C is a cyclic group optionally having substituent(s), R¹ is a hydrogen atom, a hydrocarbon group optionally having substituent(s), an acyl group, a heterocyclic group optionally having substituent(s) or an amino group optionally having substituent(s), R² is an optionally halogenated C_1-6 alkyl group, m and n are each an integer of 0 to 5, m+n is an integer of 2 to 5, and

is a single bond or a double bond, or a salt thereof and the like. Since the compound has a superior tachykinin receptor antagonistic action, and is useful as an agent for the prophylaxis or treatment of various diseases such as lower urinary tract diseases, gastrointestinal diseases, central nervous system diseases and the like.

Provided is an agent for treating or preventing urinary frequency, urinary urgency and urinary, incontinence which are associated with overactive bladder, a lower urinary tract disease such as interstitial cystitis and chronic prostatitis accompanied by lower urinary tract pain, and various diseases accompanied by pain. A novel azolecarboxamide derivative in which an azole ring such as thioazole or oxazole is bonded to a benzene ring, pyridine ring or pyrimidine ring through carboxamide was confirmed to have a potent trkA receptor-inhibitory activity and found to be an agent for treating or preventing lower urinary tract disease and various diseases accompanied by pain, which is excellent in efficacy and safety, and thus the present invention was accomplished.

A novel dietary supplement or therapeutic composition is provided that serves to treat lower urinary tract disorders or to support normal urinary tract function in animals. The supplement comprises a thymoquinone formulation and at least one member of the group consisting of cranberry fruit, cranberry extract, cranberry juice and a pharmaceutical grade methionine.

The invention relates to the technical field of animal feed, in particular to urinary tract health maintenance nutritional health-care food for dogs and cats and a preparation method of the food. The health-care food consists of the following components in percentage by mass: 10 to 30 percent of chickens, 10 to 50 percent of grains, 5 to 20 percent of vegetable protein, 5 to 20 percent of chicken fat, 5 to 15 percent of egg powder, 0.5 to 5 percent of Indian Buead, 0.5 to 5 percent of bighead atractylodes rhizome, 0.5 to 5 percent of semen plantaginis, 0.5 to 5 percent of rhizoma alismatis, 0.5 to 5 percent of akebiaquinata, 0.5 to 5 percent of rhizoma atractylodis, 0.5 to 5 percent of mangnolia officinalis. 0.5 to 5 percent of ophiopogon japonicus, 0.5 to 5 percent of pericarpium citri reticulatae, 0.5 to 5 percent of liquorice, 1 to 5 percent of spinach, 1 to 5 percent of carrot, 0.5 to 5 percent of beer yeast, 0.2 to 0.5 percent of fructooligosaccharide, 0.5 to 5 percent of vitamin and 0.5 to 5 percent of mineral. The invention starts with the nutritional diet for maintaining the urinary tract health by aiming at the inducement of urinary tract diseases of the dogs and cats, and selects a fully-nutritional special formula prepared by the natural eatable plants so as to maintain the urinary tract health of the dogs and cats. After the food is fed, the technology provided by the invention takes effect on maintenance of the urinary tract health of the dogs and cats.

The present invention relates to a disorder of the lower urinary tract, and in particular, reducing the symptoms (including treatment) of interstitial cystitis in vivo. In a preferred embodiment, the present invention relates to treatment formulations and methods for reducing interstitial cystitis in patients via administration of a therapeutically effective concentration of PRG4.

A composite litter material for detecting a disease, such as urinary tract disease, when contacted by feline urine includes an absorptive polymer material forming a solid matrix, exfoliated clay embedded and dispersed within the solid matrix, a chromogenic indicator provided within the solid matrix, and an oxidizing agent distributed and stabilized within the solid matrix to be responsive to peroxidase activity in the urine to activate the chromogenic indicator. A method for detecting or diagnosing a feline disease includes contacting urine with the material and detecting a color change. A method of manufacturing the composite material includes preparing a mixture comprising the absorptive polymer and water and distributing the exfoliated clay, chromogenic indicator and oxidizing agent within the mixture, preferably by extrusion and addition of the components at particular points in processing the polymer mixture.

Compounds represented by the general formula (I):

wherein each symbol is as defined in the description [with the proviso that 9-chloro-7-(1,1-dimethylethyl)-2,3,4,5-tetrahydro-1,4-benz-oxazepine and N-[[(5S)-2-oxo-3-(2,3,4,5-tetrahydro-1,4-benz-oxazepin-7-yl)-5-oxazolidinyl]methyl]acetamide are excluded], salts of the same, and prodrugs thereof have selective activation effect on serotonin 5-HT_2C receptor and are useful as preventive and therapeutic agents for lower urinary tract diseases, obesity, and/or pelvic organ prolapse.

The invention relates to the field of urogenital system and lower urinary tract diseases. The invention provides a new medicinal composition. The composition comprises medicinal effective compositionof the following substances: I) a first compound selected from medicaments for treating bladder hyperactivity such as muscarinic receptor antagonist and medicaments for treating prostate hyperplasia such as 5alpha-reductase inhibitor and alpha-adrenergic receptor antagonist, precursors thereof and pharmacologically acceptable salts thereof, II) a second compound selected from PDE-5 enzyme antagonist, precursor thereof and pharmacologically acceptable salt thereof, and III) a second compound selected from antidiuretic, precursor thereof and pharmacologically acceptable salt thereof, and optional pharmacologically acceptable vector thereof or diluent. The three medicaments can be combined two by two (such as I + II, or I + III, or II + III), or combined together at the same time (such as I +II + III). The invention also provides a group of methods for treating urogenital system and lower urinary tract diseases of mammals comprising people, wherein the methods comprise applying treatmenteffective dose of the composition to the mammals comprising people needing the treatment.

The present invention is directed to a pharmaceutical composition comprising: (1) a therapeutically effective quantity of sodium pentosan polysulfate; (2) a quantity of a penetration enhancer sufficient to improve the bioavailability of the sodium pentosan polysulfate; and (3) optionally, a pharmaceutically acceptable carrier and to methods for the oral administration of sodium pentosan polysulfate with improved bioavailability for the treatment of interstitial cystitis and other urinary tract diseases and conditions. Such compositions and methods allow the administration of sodium pentosan polysulfate at lower dosages to reduce the frequency and severity of side effects.

[Object] To provide a therapeutic and/or prophylactic agent for urinary frequency, urinary urgency, and urinary incontinence associated with various lower urinary tract diseases including overactive bladder, various lower urinary tract diseases accompanied by lower urinary tract pain, such as interstitial cystitis, chronic prostatitis, and the like, and various diseases accompanied by pain, based on an excellent trkA receptor inhibitory action.

[Means for Solution] A novel azolecarboxamide compound in which a thiazole ring or an oxazole ring is bonded to a benzene ring, a pyridine ring, a pyridazine ring, a thiophene ring, a pyrazole ring or a pyrrole ring through carboxamide, or a salt thereof is confirmed to have a potent trkA receptor inhibitory activity, and found to be capable of being used as a therapeutic and/or prophylactic agent which is excellent in efficacy and safety for urinary frequency, urinary urgency, and urinary incontinence associated with various lower urinary tract diseases including overactive bladder, various lower urinary tract diseases accompanied by lower urinary tract pain, such as interstitial cystitis, chronic prostatitis, and the like, and various diseases accompanied by pain, thereby completing the present invention.

An N-phenylarylsulfonylamide compound of formula (I)

(R¹ is COOH etc.; R² is hydrogen, methyl, etc.; R³ and R⁴ are a combination of methyl and methyl, etc.; R⁵ is isopropyl etc.; Ar is thiazolyl, pyridyl, 5-methyl-2-furyl each optionally substituted with methyl; n is zero or 1), a synthetic intermediate for the compound and a process for its preparation. The compound of formula (I) binds to a prostaglandin E₂ receptor, especially an EP₁ subtype receptor, and antagonizes it. It is less affected by protein binding, so it has a satisfactory in vivo activity. Therefore, it is considered to be useful as an analgesic, an antipyretic agent, an agent for the treatment of pollakiuria (frequent urination) and/or lower urinary tract disease syndrome or an antineoplastic agent.

A non-invasive method for detecting disease of the excretory urinary tract and presence of renal calculi is provided. According to the method, the presence or concentration of one or more TFF peptides from among TFF1, TFF2, and TFF3 is determined in a urine sample, the presence or concentration being indicative of urinary tract disease or presence of renal calculi.

An improved method of treating lower urinary dysfunctional epithelium (LUDE) or a disease, condition, or syndrome associated with LUDE, including interstitial cystitis, comprises the step of administering orally a pharmaceutically effective quantity of heparin to a patient in need of treatment for LUDE or a disease, condition, or syndrome associated with LUDE in order to treat LUDE or a disease, condition, or syndrome associated with LUDE. The heparin can be administered together with a quantity of a penetration enhancer that is sufficient to result in a tissue concentration of heparin that is sufficient to treat LUDE or a disease, condition, or syndrome associated with LUDE. A suitable penetration enhancer is sodium N-[8-(2-hydroxybenzoyl)amino]caprylate. The method can further comprise the administration of at least one additional pharmaceutical composition to treat LUDE or a disease, condition, or syndrome associated with LUDE The invention further includes a pharmaceutical composition comprising: (1) a quantity of heparin that is pharmaceutically sufficient for the treatment of LUDE or a disease, condition, or syndrome associated with LUDE; and (b) at least one filler, excipient, or carrier; wherein the pharmaceutical composition is formulated for the treatment of LUDE or a disease, condition, or syndrome associated with LUDE.

The invention discloses cat litter for detecting urinary tract diseases of cats and a preparation method of the cat litter. The cat litter comprises the following components in parts by weight of 350-400 parts of an agricultural solid material, 15-25 parts of an adhesive, 3-8 parts of a preservative and 3-8 parts of an occult blood detection reagent. According to the cat litter for detecting the urinary tract diseases of the cats, agricultural and forestry waste is used as main raw material sources, so that the cat litter is safe, non-toxic, environment-friendly and recyclable, the preparation method of the cat litter is simple, product particles are small, and the cat litter better conforms to the use habits of the pet cats. Meanwhile, a trace amount of detection reagent is added, the occult blood in urine can be detected, owners are helped to perceive the urethral diseases of the pet cats in time, treatment is conducted early, and the service life of the pets is prolonged.

The invention discloses a crystal form of a heterocyclic compound as well as a preparation method and application of the crystal form. The crystal form of the compound is as shown in a formula A. The crystal form is a crystal form I, a crystal form II, a crystal form III, a crystal form IV, a crystal form V, a crystal form VI, a crystal form VII, a crystal form VIII or a crystal form IX. The invention discloses a preparation method of the crystal form, a composition and application of the crystal form in preparation of a P2X3 receptor antagonist. The invention also relates to the application of the compound in preparation of medicines for preventing and/or treating pains, urinary tract diseases or respiratory system diseases. The P2X3 receptor antagonist has the advantages of high P2X3 antagonistic activity, good selectivity, low toxicity, good metabolic stability and small taste influence.